Zachariah P K, Sheps S G, Oshrain C, Schirger A, Stein W J
Division of Hypertension and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
J Clin Hypertens. 1987 Dec;3(4):536-46.
The antihypertensive effects of immediate-release (IR) verapamil were compared with those of sustained-release (SR) verapamil in 58 patients. After an open-label (IR verapamil) study, patients were randomized into a double-blind study to continue receiving the same dose of IR verapamil three times daily or an equivalent dose of SR verapamil (240 to 480 mg) once daily. Blood pressure decreased from 149/98 to 139/90 mmHg (p less than 0.01) with IR verapamil and from 150/98 to 136/88 mmHg (p less than 0.01) with SR verapamil. Ambulatory blood pressure monitoring showed a similar response for the two formulations. Diastolic pressure was less than 90 mmHg in approximately 67% of the IR verapamil group and 61% of the SR verapamil group. Mean trough plasma concentrations of verapamil were 70 and 59 ng/ml at 2 and 4 weeks, respectively, after treatment with IR verapamil; the corresponding values were 70 and 94 ng/ml for the SR verapamil group. SR verapamil administered once daily is an effective antihypertensive medication in a selected group of patients and could afford better compliance.
在58例患者中比较了速释型（IR）维拉帕米与缓释型（SR）维拉帕米的降压效果。在一项开放标签（IR维拉帕米）研究之后，患者被随机分为双盲研究组，继续每日三次接受相同剂量的IR维拉帕米或每日一次接受等效剂量的SR维拉帕米（240至480毫克）。使用IR维拉帕米时血压从149/98 mmHg降至139/90 mmHg（p<0.01），使用SR维拉帕米时血压从150/98 mmHg降至136/88 mmHg（p<0.01）。动态血压监测显示两种制剂的反应相似。IR维拉帕米组约67%的患者舒张压低于90 mmHg，SR维拉帕米组为61%。用IR维拉帕米治疗后，2周和4周时维拉帕米的平均谷浓度分别为70和59 ng/ml；SR维拉帕米组的相应值为70和94 ng/ml。每日一次服用SR维拉帕米对部分患者是一种有效的降压药物，且顺应性更好。
